Malaria vaccine? by Smith, N.J.
The crescentshaped spore- 
zoite stage of the malarra 
parasrte, the form injected by 
a mosqurto. The roughened 
surface of the sporozmte on 
the left is the result of attack 
by anbbodres: a potentlai 
vaccine at work. ~hofo NW pork 
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THE KING IS THREATENED 
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he king of diseases,” 
malaria, the single largest 
cause of disease and 
death in the world, received royal treat- 
ment inCalgary,Alberta,attheXI Inter- 
national Congress for Tropical Medicine 
and Malaria last fall. The congress, 
supported in part by IDRC, brought 
1500 health professionals represent- 
ing 68 countries to participate in almost 
300 seminars and workshops cover- 
ing all the major tropical diseases. 
Thirty of the sessions dealt specif- 
icallywith the malarial parasite and its 
Anopheies mosquitovector.Topics on 
malaria covered the entire spectrum of 
genetics, epidemiology, chemotherapy, 
health care delivery and training and, 
most publiczed of all, vaccine devel- 
opment. 
At the opening ceremonies, Nobel 
Prize winner Dr (Sir) Gustav Nossal, 
Director of the Walter and Eliza Hall 
Medical Research Institute, Victoria, 
Australia, set the theme: “Vaccines are 
history’s most cost-effective public 
health tool. The importance of a malaria 
vaccine compares to that of the Salk 
vaccine.” 
Just how close the world is to enjoy- 
ing such a health advancement was 
reported at the congress for vaccines 
to all three major stages of the parasite’s 
complex life cycle. 
However, in his opening address, Dr 
Adetokundo Lucas, Director of WHO’s 
Special Program for Research and 
Training in Tropical Diseases (ID@, 
warned, “It would be hazardous even 
at this stage to attempt to predict when 
the first trial of a malarial vaccine will 
take place in humans, or when such 
vaccines could be expected to come 
Into operational use. What can be said 
emphaticallyisthatmoreprogress has 
been made towards the development 
of malaria vaccines in the past decade 
than in the preceding 100 years.” 
Most advanced is the antisporozoite 
vaccine being developed by the team 
of Drs Ruth and Victor Nussensweig of 
New York University Medical Center 
(NYU) and groups at the National 
Institutes of Health and Walter Reed 
Army Institute of Research in Wash- 
lngton. The thread-like single-celled 
sporozoite is the stage of the Plas- 
medium parasitethat enters the blood- 
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stream when an infected mosquito 
bites. 
In several congress papers. Dr Ruth 
Nussensweig and members of her 
research team gave biotechnical de- 
tails of their work that has led to the 
identification of the main antigen 
involved in stimulating the body’s 
immune system to produce protective 
antibodies against spororoites of 
Plasmodium falciparum, the most 
deadlyofthe human malarial parasites. 
Previously, this team identified similar 
antigen-antibody reactions for several 
other primate and human species of 
malaw 
The falciparum antiqen is a “cir- 
cumsporozoite” (cs) protein, part of a 
familyof proteins that covers thewhole 
surface membrane of the parasite. As 
was widely publiwed in August of 
1984, the NYU researchers reported 
they have also determined the bio- 
chemical nature of the antigen and the 
genetic code within the parasite’s DNA 
that directs its productlon. Nussensweig 
further noted that, although the malarial 
antigen-antibody reactions appear to 
be species-specific, fortunatelyforthe 
production of an effective vaccine, the 
several strains of Plasmodium falciparum 
around theworld possess almost Iden- 
tical immunogenic antigens. 
Critics of the vaccine have stated 
that sporozoites are in the blood stream 
for too short a time (several minutes) to 
stimulate an immune reaction before 
they penetrate liver cells and are pro- 
tected from any further detection. In 
her discussion period, Nussensweig 
countered with a report that 90 percent 
of adults over 20 years old in heavily 
malaria-infested Gambia have antl- 
bodies to sporozoites. “That indicates 
a definite sporozoite-induced immune 
reaction,” she said. 
In her paper. Nussensweig suggest- 
ed three possible methods for produc- 
ing large enough amounts of antigen 
to be used for a vaccine. The NYU 
researchers have already synthesized 
the cs protein using conventional 
laboratory biochemistry. And, using 
genetic engineering techniques, they 
have inserted the antigen’s gene into a 
strain of E. co/i bacteria. which allows 
mass production of the antigen in the 
future. A third method would be to 
insert the antigen’s gene into the DNA 
of vaccinia virus, used in the past to 
vaccinate against smallpox. In a later 
discussion, she suggested that her 
vaccinewould be best administered to 
high-risk groups with little natural 
immunitvto malaria, i.e..vounq children, 
pregnant women, and fdreigt?travellers 
into an infested area. The NYU team will 
begin trials of the proto-vaccines in 
humans within the year. 
Life cycle of the malaria parasite, Plasmodium. An infected Anopheles mosquito 
(below) bites a vulnerable host and injects sporozoites. Quickly, the sporozoites move 
through ihe bloodstream to the liver. where they change into schizonts. Then they 
emerge into the bloodstream again, wade and destroy red blood cd/S, and burst forth 
into the bloodstream as merozoltes seeking new red blood ceils to invade. A few 
parasites change into the Qametocyte form and enter the bloodstream. If picked up by 
a mosquito these parasites can multiply and infect the nexf person the mosquito bites. 
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Such a sporozoite vaccine would 
protect against the initial malarial in- 
fection. Butwhatwould happen,critics 
ask, if a vaccinated person’s immune 
system acted slightly sluggish and 
allowed a sporozoite to escape into a 
liver cell? One sporozoite alone is ca- 
pable of dividing and releasing into 
the blood 30000 merozoites, the 
parasite’s second, asexual stage, 
which generates the actual malarial 
symptoms of chills and fever through 
cyclic invasions and destruction of red 
blood cells. 
Because the sporozoite vaccine 
may not be totally effective, a second 
Vaccine is being developed, reported 
Dr Robin F. Anders. Joint Head of the 
Malarial Team at the Walter and Eliza 
Hall Medical Research Institute, Vic- 
toria, Australia One handicap in real candidates to use to make vac- 
developing this vaccine, said Anders, 
is that, unlike the sporozoite stage, the 
tine.” In the next year they plan to 
asexual stage has demonstrated “a 
begin monkey experiments to test the 
bewildering array of antigens on its 
immunogenic action of these antigens. 
surface,” including a great deal of 
Dr Nossal, director of this institute, 
cautioned that “a merozoite vaccine 
lnterstratn variability. Surface antigens 
differ even between parasite cells with 
won’t necessarily stop the disease 
the same DNA. Somehow the cells are 
completely. At the worst, a patient 
turning on or off different sections of 
would have a less violent type of dis- 
the DNA that codes for antigen protein. 
ease, maybe a transient headache.” 
“A single clonal line can change its 
Henoted thatverylikelythespororoite 
spots, so to speak,” explained Dr 
and merozoite stage vaccines would 
be given in combination for best pro- 
Anders. Because of this complexity, tection. 
researchers still have not isolated a 
single merozoite antigen that could 
How far along is the second vaccine 
serve alone as an effective vaccine. 
compared to the Nussensweig vac- 
However, Anders said that his team 
tine? ” We’ll be field testing in three 
“does have a number of antigens 
years, probably,” said Nossal. “The 
end of the decade is not an unrealistic 
em, are several time to expect us to have a ready vac- 
1111 W&P 1 year or two behind 
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of London’s School of Hygiene and 
accine would 
Jai stage of malaria, 
uito when it 
n. “This 
Tropical Medicine.Thlsv, 
workagainst the sex, 
transmitted to a mosq~ 
feasts on an infected perso 
vaccine won’t do the infected person 
any good,” said Targett,“but it will stop 
transmission of the disease.” The 
amount of antigenic variation in this 
parasite stage appears to be some- 
where between that of the other two 
stages. Potential immunogenic anti- 
gens have been isolated for intensive 
in vitro and in viva testing. 
Scientists and health workers at the 
congress were cautious in theirassess- 
ment of the potential vacc 
no one knows as ye 
ties. e.a.. stabilitv. mode 
mes because 
:t their final proper- 
I, of administra- 
tion, or length oi’time they will convey 
irr lmunlty. 
Dr Max hjillw congress president, -. ..-.. _., _ 
said, “Immunization is the simplest 
way to prevent disease, but people 
shouldn’t be too optimistic about 
malaria vaccines.” For example, he 
pointed out, if the vaccines require a 
“cold chain,” constant refrigeration, 
delivery in the rural tropics could be a 
major problem. “People are grabbed 
by the glamour of these vaccines but 
overlook the fact that unglamorous 
Solutions are responsible for much of 
the health imorovements in undevel- 
oped count&s.” 
In case vaccines are not the dreamed- 
for success, congress participants 
presented papers on a variety of other 
types of malarial control. 
In the symposium on malarial chemo- 
therapy and chemoprophylaxis, the 
session’s chairman, Dr W. Peters, 
Head of Medical Protozoology at the 





and Trooical Medicine, stressed the 
With a budget of $2 6 mlllion for 
1984-85. thetroplcal and infectious 
diseases program IS the second 
largest area of research supported 
by IDRC’S Health Sciences Division. 
Over the years, support has been 
given for research unto the etiology 
(causes), epidemiology (incidence 
and distribution). diagnosis, treat- 
ment. and control of a number 01 
Important tropical diseases. These 
include schistosomiasis, trypano~ 
somiasis (African and American) 
le!shmaniasls. filariasis (including 
onchocerciasis), malaria, and lep~ 
growing’problem of drug resistance. In 
the future, any new antimalanal drug 
will have to be used in combination 
with other antimalarials to slow down 
the development of resistance. 
rosy. 
IDRC has funded individual re- 
search projects on all but two oi 
these diseases. In the case of malaria 
and leprosy. IDRC support has beer 
channelled through the World Health 
Orgamzation’s Special Programme 
for Research and Training in Tropi- 
cal Diseases. 
I 
In the area of infectlow diseases 
IDRC places much emphasis or / 
studies of the etiology, epidemiol 
ogy, and control of diarrhea1 dis 
ease, which continues to be a majo 
killer of children under five. Re- 
search on acute respiratory lnfec- 
tlons and tuberculosis is also being 
advanced in all geographical re 
gions. In addition, the growins 
mcidenceofthe hemorrhagicvariet\ 
of dengue fever during epidemtcs 
especially in Southeast Asia ant 
theCaribbean,hasspawnedanum 
ber of projects on the epldemlology 
and diagnosis of this SometimeS 
fatal viral disease 
Within the tropical and infectious 
diseases program, 1Dw2 is also sup- 
porting research into the increasingly 
serious problem of sexually trans~ 
mitted disease (STD). At present. 
many developing countries do not 
have proper diagnostic and control 
programs in place. In the case of 
gonorrhea, the problem has been 
compounded. I” some regions, by 
the spread of penicillin-resistant 
strains. lowsupported work has 
therefore focused mainly on the 
diagnosis and treatment of gonor- 
rhea in Africa, Southeast Asia and, 
in particular, Latfn America. 
Finally, the tropical and infectious 
Reports on the geographlcal dis- 
trlbution of drug resistance showed 
that chloroquine-resistant P. falciparum 
strains have spread to all continents In 
the tropics. Cross-resistance to other 
antimalarials is also growing. In Africa, 
where a resistant strain was only 
detected I” 1976,the number of malaria 
cases is increasing dramatically. On 
the Thailand-Kampuchean border, 
almost all faiciparum isolates are 
resistant to chloroqulne and generally 
Fansidar. In some areas this resis- 
tance even extends to quinine. Health 
workers are forced to treat many cases 
with the expensive combination of 
quinineand tetracycline.Thus theoffi- 
diseas& program IS supporting 
research on vaccines and vaccina- 
tion programs. Important work in 
this area has Included the develop- 
mentof a time-temperature indicator 
that allows health workers to tell at a 
glance whether a vaccine has 
spoiled or not. IDRC IS also funding 
work on the deveopment of urn- 
proved yellowfevervaccine I” South 
America and studies on the effecm 
i 
cial WHO policy now is to restrict 
quinine use to keep it effective as a 
drug of last resort. 
There were also disturbing reports 
from Thailand suggesting pockets of 
Mefloqulne resistance. To delay any 
further resistance developing to this 
newest of the licensed antimalarlals, 
health officials now plan to admimster 
Mefloquine only in combination wth 
other drugs, such as the Mefloqulne- 
Fansidarformulation that will be ragIs- 
tered by the end of 1984 as “Fansimef.” 
Fortunately, there are no signs as yet of 
resistance to the still experimental 
drug halofantrine. 
Several speakers urged much closer 
monitoring of the spread of falclparum 
resistance by using the new, easy-to- 
use “micro-kits” for detecting parasite 
resistance to several drugs in the 
field. 
Unfortunately for the goal of malaria 
control, drug-resistant strains of the 
parasites are proving to be far hardier 
and faster growing than their sensitive 
relatives. 
The best news was that still newel 
antimalarials are on the horizon. in- 
cludln( 3 derivatives of an anclent 
Chinese herbal medicine that seem to 
be effective against both P. faiciparum 
and P. vivax, the milder human parasite 
responsible for relapsing malaria. Dr 
T.M. Cosgriff of the US Army’s anti- 
malarial drug program reported that 
the army IS also testing 30 compounds 
that show a great deal of promise. And 
Dr W.E. Gutteridge of the Wellcome 
Foundation countered critics assert- 
ing that pharmaceutical companies 
are doing little antImalarial research 
by reporting on his survey of 16 inter- 
nationally known companies. Results: 
eight companies are actively develop- 
ing new drugs, five of them making 
final adjustments on specific drugs, 
such as eliminating side effects, or 
rnprovlng absorption. 
In discussion, Dr W.H. Wernsdorfer, 
Chief of WHO’S Malaria Research Unit, 
warned that the poorer countries will 
be the hardest hit if drug resistance is 
allowed to spread unchecked, forcing 
a shift from treatment with chloroquine 
to the next lowest-cost drug, which is 
still five times more expensive. 
Later, London’s Dr Peters reminded 
his audience that “it IS vital that sole 
reliance should not be wlaced on 
drugs to limit the transmission of the 
pool of malaria.” Instead he recom 
mended more health education, more 
direct participation of communities in 
their own control programs, and vac- 
clnatlon. 
Among the other methods of malaria 
control discussed at the congress was 
the less-human-oriented procedure of 
vector control. Several papers report- 
ed attempts to raise strains of genet- 
ically altered mosquitoes that were, for 
example, more resistant to malarial 
parasites, but these “pampered, pet- 
ted” lab-bred strains have proven to be 
no match reproductively for wild mos- 
quitoes. In general, researchers em- 
phasized the importance of studying 
theecologyand behaviourofthemany 
Anopheies species if there were to be 
any major gains in future vector con- 
trol. Scientists are finding that species 
compositlon and numbers vary with 
such practices as forest cutting, ur- 
banization and large-scale irrigation 
projects, but no one still is sure what 
really IS the critical mosquito density 
that maintains malarial transmission. 
The basis of innate resistance to 
malaria infections in humans was even 
probed, butthesessions demonstrated 
just how much we still have to learn 
about this ancient disease. 
Yet despite the obvious difficulty of 
the campaign to reduce malaria, at the 
end of the congress participants were 
commltted to continue. Dr Nossal con- 
cluded that”we‘re talking about a dis- 
ease that’s shaped human history over 
several million years. If we could eradl: 
cate malaria, it would be like killing 
one of the worst enemies of our 
species. It might have as much Impact 
as the death of the dinosaurs.” 0 
Nancy Johnson Smrth IS a Calgary-based 
wirter and audiovrsuai consultant. 
